Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ALEXION PHARMACEUTICALS, INC. | alxnex99110-ka12312020.htm |
| EX-31.4 - EX-31.4 - ALEXION PHARMACEUTICALS, INC. | alxnex31410-ka12312020.htm |
| 10-K/A - 10-K/A - ALEXION PHARMACEUTICALS, INC. | alxn-20201231.htm |
Exhibit 31.3
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Ludwig Hantson, certify that:
1.I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A for the year ended December 31, 2020 of Alexion Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
| Dated: | February 16, 2021 | /s/ LUDWIG N. HANTSON, Ph.D. | |||||||||
| Chief Executive Officer | |||||||||||